New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Iomai (IOMI)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for Iomai
Accounts Receivable
Additional Indications
Administration Eligibility
Agreement Purchase Sell Stock
Amendment 2005 Stock Incentive Plan
Amendment Facility Lease
Annual Bonus
Annual Incentive Bonus
Antibody Response Toxin After Vaccination
Attendance Board Meetings
Audit Fees
Audit-related Fees
Availability Periodic Sec Reports
Award Government Contract
Base Salary
Basic Diluted Net Income Loss Attributable Common Stockholders
Basic Diluted Net Loss Attributable Common Stockholders Per
Because Not Expect Pay Dividends Foreseeable Future Rely
Beneficial Ownership Reporting Compliance
Biopharmaceutical Limited Operating History Generated Revenue Product Sales
Business Exposes Potential Product Liability Claims
Cash Equivalents
Cautionary Statement Regarding Forward-looking Statements
Certain Relationships Related Transactions
Certificate Amendment
Change Control Arrangements 2005 Incentive Plan
Changes Internal Controls Over Financial Reporting
Chief Executive Officer
Chief Executive Officer Compensation
Closing
Code Business Conduct Ethics
Commitment Good Corporate Governance
Committees Board
Communications Board
Comparison 2004 2003
Comparison 2005 2004
Comparison 2006 2005
Comparison Cumulative Total Return Iomai Corporation Nasdaq Stock
Compensation Chief Executive Officer
Compensation Committee Interlocks Insider Participation
Compensation Committee Report
Compensation Committee Report Executive
Compensation Components
Compensation Objective
Compensation Other Executive Officers
Competition
Competitors Superior Products Manufacturing Capability Marketing Expertise
Complaint Procedures
Comprehensive Loss
Concentration Credit Risk Fair Value Financial Instruments
Conclusion
Conditions Obligations Closing
Conditions Purchasers Obligations Closing
Consideration Director Nominees
Corporate Information
Critical Accounting Policies Estimates
Deal Hazardous Materials Cause Injury Others Regulated Environmental
Depend Key Personnel Loss Adversely Affect Operations Fail
Description Proposed Amendments Plan
Determination 2006 Compensation
Director Attendance Annual Meetings
Director Compensation
Director Compensation Policy
Directors Management Exercise Significant Control Over
Disclosure Controls Procedures
Documents Incorporated Reference
Duties Responsibilities
Election Directors
Employee Stock Purchase Plan
Employees
Employment Agreements Change Control Arrangements
Enhanced Immune Responses Elderly After Patch Application
Entry Material Definitive Agreement
Estimates
Exact Name Registrant Specified Charter
Executive Officers Registrant
Executive Sessions Independent Directors
Expect Stock Price Fluctuate Significantly Adversely Affect Holders
Experience Sales Marketing Distribution Depend Efforts Parties
Facility Sublease
Federal Income Tax Consequences Relating 2005 Incentive Plan
Financial Operations Review
Financial Statements Exhibits
Financing History
Form 10-k
Function
General Administrative Expense
General Philosophy
Governance Guidelines
Government Agencies Special Contracting Requirements Create Additional Risks
Government Regulation
Grants Plan-based Awards
Historical Results Operations Liquidity Capital Resources
History Operating Losses Never Profitable
Immune System Vaccines
Immunostimulant Patch Elderly Receiving Flu Vaccines
Incentive Plan
Income Taxes
Indemnification Officers Directors
Independence Directors
Independent Directors
Independent Registered Public Accounting Firm
Index Financial Statements
Influenza
Influenza Elderly
Initial Public Offering
Initial Target Markets
Involved Lawsuits Protect Enforce Patents Collaborators Licensors Expensive
Iomai Corporation
Iomai Corporation Securities Purchase Agreement
Key Responsibilities
License Tci Technology Walter Reed Army Institute Research
Long-term Equity Incentives
Management Oversight
Management Review 2006
Manufacturing Commercial Supply
Market Overview
Marketable Securities
Membership
Need Additional Funding Cannot Guarantee Find Adequate Sources
Needle-free Flu Vaccine Patch
Needle-free Pandemic Flu Vaccine Patch
Needle-free Travelers Diarrhea Vaccine Patch
New Plan Benefits
Nominees Class Directors Terms Expire 2010
Nominees Election Directors
Nonqualified Deferred Compensation
Not Able Manufacture Product Candidates Commercial Quantities Prevent
Not Achieve Projected Development Goals Time Frames Announce
Notice Annual Meeting Stockholders
Option Exercises Year-end Values
Option Grants
Option Grants Exercises
Options Exercised Stock Vested
Organization
Organization Governance
Other
Other Compensation
Other Events
Other Executive Officers
Other Fees
Other Matters
Overview
Pandemic Flu
Part
Part Product Development Efforts Make Significant Changes Candidates
Patch Elderly Receiving Flu Vaccines
Patch Pandemic Flu
Patch Pandemic Flu Program Relies Government Health Organizations
Performance Board
Physicians Patients Not Accept Products Unable Generate Significant
Plan Distribution
Plans Funds Continue Clinical Development Novel Patch- Based
Powers Compensation Committee
Powers Corporate Governance Committee
Preferred Stock
Price Volume Common Stock Experience Extreme Fluctuations Then
Private Placement
Private Placement Public Equity
Product Candidates Been Approved Commercial Sale Never Receive
Products Approved Commercial Sale Subject Penalties Fail Comply
Products Development
Property Equipment
Provisions Delaware Law Charter Documents Delay Prevent Acquisition
Proxy Statement
Purpose
Recent Accounting Pronouncements
Recently Began Developing Manufacturing Heat Labile Toxin Not
Recently Began Testing New Formulation Tci Patch Technology
Recitals
Related Party Transaction Policies Procedures
Related Party Transactions
Rely Parties Conduct Clinical Trials Those Third-parties Not
Report Audit Committee
Report Independent Registered Public Accounting Firm
Representations Warranties Certain Agreements Purchasers
Required Conduct Clinical Trials Patch Flu Vaccines Developed
Research Development Costs
Research Development Expenses
Restricted Cash Marketable Securities
Results Operations
Revenue Recognition
Revenues
Role Board Directors
Rule 14a-101
Sale Series Preferred Stock Elan
Sales Marketing
Schedule Purchasers
Securities Authorized Issuance Equity Compensation Plans
Separate Copies Beneficial Holders
Series Convertible Preferred Stock
Series Convertible Redeemable Preferred Stock
Series Preferred Stock Warrants
Signature Page Securities Purchase Agreement Dated 2006 Among
Signatures
Skin Preparation Systems Used Connection Product Candidates Make
Skin Pretreatment Methods Used Connection Product Candidates Make
Special Meeting Stockholders
Statement Purpose
Stock Compensation
Stock Incentive Plan
Stock Option Plan
Stock Options
Stock Performance
Stock Performance Graph
Stock Warrants
Stock-based Compensation
Stockholder Communications Board
Stockholder Proposals
Stockholder Proposals 2008 Annual Meeting
Strategy
Summary Compensation Executive Officers
Summary Existing 2005 Incentive Plan
Table Contents
Tax Fees
Tci Solution
Technology Conflicts Intellectual Property Rights Parties Incur Substantial
Technology Unproven Presents Challenges Product Development Efforts
Termination Based Compensation
Travelers Diarrhea
Unable Protect Confidentiality Proprietary Information Know-how Value Technology
Unable Protect Intellectual Property Not Able Operate Business
Unregistered Sales Equity Securities
Vote Required
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour